Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

10.86 -0.04 (-0.32%)
Streaming Delayed Price Updated: 11:09 AM EST, Jan 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocular Therapeutix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix™ To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Earnings Scheduled For February 28, 2022 ↗
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
News headline image
Expert Ratings For Ocular Therapeutix ↗
Ocular Therapeutix (NASDAQ:OCUL) has observed the following analyst rating... 
Via Benzinga
News headline image
Earnings Scheduled For May 9, 2022 ↗
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million. 
Via Benzinga
News headline image
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Gainers Ocular Therapeutix (NASDAQ:OCUL) shares moved upwards by 12.3% to $4.01 during Friday's after-market session. The company's market cap stands at $307.7 million. 
Via Benzinga
News headline image
Ocular Therapeutix™ to Report First Quarter 2022 Financial Results
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix™ to Present Pre-Clinical and Clinical Data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More ↗
Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting... 
Via Benzinga
News headline image
Ocular Therapeutix™ to Present Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
On Thursday, 236 companies hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new... 
Via Benzinga
News headline image
Recap: Ocular Therapeutix Q4 Earnings ↗
Ocular Therapeutix (NASDAQ:OCUL) reported its Q4 earnings results on Monday, February 28, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
News headline image
Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2021 Financial Results
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2022 Meeting and OTX-TIC Phase 1 Clinical Trial at Glaucoma 360
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week... 
Via Benzinga
News headline image
AffaMed Therapeutics, licensee of DEXTENZA® in Certain Asian Markets, Doses Their First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA® in China in Cataract Surgery Patients
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix™ to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix's Dexamethasone Ophthalmic Insert Meets Primary Goal In Dry Eye Disease Trial ↗
Ocular Therapeutix Inc (NASDAQ: OCUL) announced topline results from its Phase 2 trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-... 
Via Benzinga
News headline image
Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Disease
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix™ to Participate at Two Upcoming Investor Conferences
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix Stock Gains As Court Invalidates Drug Delivery Patent From Mati ↗
Ocular Therapeutix Inc (NASDAQ:OCUL) announce... 
Via Benzinga
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Frequency Therapeutics (NASDAQ:FREQ) stock rose 10.94% to $7.51 during Tuesday's regular session. The current volume of 277.7K shares is 160.43% of Frequency... 
Via Benzinga
News headline image
Ocular Therapeutix™ Announces Success in Patent Appeal Brought by Mati Therapeutics, Inc.
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix: Q3 Earnings Insights ↗
Ocular Therapeutix (NASDAQ:OCUL) reported its Q3 earnings results on Monday, November 8, 2021 at 04:01 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
News headline image
Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results and Business Update
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix™ Announces Update from the Centers for Medicare and Medicaid Services (CMS) for the Reimbursement of DEXTENZA®
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 8, 2021 ↗
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.